The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
Precision for Medicine, a leading biomarker-driven clinical research organization (CRO), received wide recognition at the prestigious 2023 CRO Leadership Awards. The awards acknowledge top CRO partners and are determined by feedback from pharma and biotech sponsors. Precision has been honored in all five categories: Capabilities, Compatibility, Expertise, Quality, and Reliability, securing awards in the Overall, Big Pharma, and Small Pharma categories, along with several distinguished Champion Awards.
This recognition serves as a testament to our commitment to quality and our clients’ trust in delivering measurable results.
Bethesda, Md., April 26, 2023 — Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointments of Stacey Hanna, General Counsel and Chief Compliance Officer, and Tina Durocher-Murphy, Chief People Officer. In these roles, Stacey and Tina are responsible for all legal and compliance and human resources functions, respectively, across the enterprise. Both leaders will report directly to Mark Clein, Chief Executive Officer of Precision Medicine Group.
“As Precision Medicine Group innovates and evolves, adding senior-level talent like Tina and Stacey contributes significantly to scaling people, process, and culture for our next phase of growth,” said Clein. “Stacey and Tina are experienced leaders who have proven track records to ensure that our people and processes are well connected to and supported for our growth trajectory.”
Even as cell and gene therapies inspire hope for patients who previously had none, the path to commercialization is littered with roadblocks. There is a pressing need for increased efficiency, enhanced safety, and innovative approach to pricing and access. How are leading CGTx innovators approaching these challenges? Find out at Cell & Gene Day 2023, a free virtual event, streaming on demand HERE.
Bethesda, Md., April 12, 2023 — Precision Value & Health, the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, today announced that it has acquired Makara Health, a UK-based international healthcare communications agency. The move will expand Precision’s European footprint and reinforce the company’s market growth position with its core capabilities in Europe. Founded in 2013, Makara has capabilities in learning and development, medical and patient education, PR and brand promotion, offering its diverse roster of healthcare client companies high-quality, strategic, scientifically robust programs, as well as creative delivery solutions.
With this acquisition, Makara becomes part of the Precision Value & Health team. The Makara team will work closely with PRECISIONscientia, an agency dedicated to delivering medical and scientific communications that expertly interpret and translate the science of medicine.
Houston is one of seven global Precision specialty labs addressing the rising demand for rapid, comprehensive biomarker data to support the development of advanced therapies and diagnostics
HOUSTON, TX, April 12, 2023 – Precision for Medicine, the first global biomarker-driven clinical research organization, today announced the expansion of its cell biology and genomics laboratory in Houston, TX, proliferating the company’s global biomarker capabilities and laboratory operations.
Gene therapies offer hope for patients with severe genetic diseases by providing long-term benefits and even cures. However, the challenges of evaluating the long-term benefits of these therapies from a payer perspective are considerable. This white paper by PRECISIONadvisors highlights the shift of gene therapy research into more prevalent diseases, and outlines how manufacturers and payers can co—create evidence requirements and models to optimize launch success and sustainability.
BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.
“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”
Stern IR, part of Precision Value & Health, enhances market leadership position by integrating IR expertise, deep biotech knowledge, and ESG solutions to bring substantive value to clients. ESG Expert Molly Podolefsky, PhD, to lead complementary new ESG capability
NEW YORK, March 2, 2023 — Stern IR, Inc., a Precision Value & Health company, today announced the launch of its new environmental, social, and governance (ESG) advisory practice. The addition of the ESG practice will deliver a suite of solutions, including materiality assessments, ESG strategy and roadmap development, reporting, and communications packages that are well integrated with Stern’s core investor relations (IR) competencies. These complementary ESG solutions are designed to meet the evolving IR needs of biotechnology and healthcare companies, which increasingly involve and are influenced by ESG considerations and factors with ESG rapidly becoming a core component of best-in-class IR.
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity.
[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.
Proven Life Sciences Leader Takes Reins to Continue Rapid Growth and
Drive Next-Gen Commercialization Model
BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.